Ocuphire Pharma Investor Day Presentation Deck
RM
Percent of Subjects (%)
MIRA-2: Responders Returning to Baseline Pupil Size by Iris Color
Nyxol Works in Subjects with Both Light and Dark Irides, with a More Vigorous Response in Light Irides
53
100%
80%
60%
40%
20%
0%
Placebo n=45|
Nyxol n=45
Light Irides (Study Eye)
Percent of Subjects Returning to ≤ 0.2 mm of Baseline
Placebo n=45
■Nyxol n=45
0.5
0%
0%
p<0.01
1
0%
31%
p<0.0001
p<0.0001
Nyxol Reverses Dilation in Light and Dark Irides
MIRA-2 Phase 3 Trial
p<0.0001
||
1.5
2
3
4
2%
7%
13%
89%
24%
96%
56%
71%
Time Post-Treatment with Nyxol/Placebo (Hours)
p<0.0001
p<0.0001
6
49%
93%
100%
80%
60%
40%
20%
0%
Placebo n=46
Nyxol n=49
Source: MIRA-2 TLR table #14.2.1.6 (MITT)
*Data includes three of the most common mydriatics used in practice (Phenylephrine, Tropicamide, Paremyd)
Dark Irides (Study Eye)
Percent of Subjects Returning to ≤ 0.2 mm of Baseline
Placebo n=46
Nyxol n=49
0.5
7%
2%
p<0.01
p<0.001
1
4%
25%
p<0.001
1.5
11%
43%
2
3
15%
22%
47%
71%
Time Post-Treatment with Nyxol/Placebo (Hours)
p<0.0001 p<0.001
4
35%
69%
p<0.0001
6
41%
88%
Ocuphire
PHARMAView entire presentation